Home » Newsletters » BioWorld Science

BioWorld Science

May 19, 2010

View Archived Issues

Regeneron provides data on two antibody product candidates

Preclinical and clinical data on dual FXR/TGR5 agonist INT-767 disclosed by Intercept

Vertex discovers novel CFTR channel modulators

New CREB-mediated gene transcription inhibitors claimed by U.S. scientists

Merck & Co. describes novel orexin receptor antagonists

Snapshots: Recent data on denosumab for postmenopausal osteoporosis

Bayer's BAY-80-6946 induces regression in tumor models

Macrolides CSY-3655 and CSY-0073 show promise in mouse models of inflammation

Fixed-dose ibuprofen/famotidine combination HZT-501 evaluated in healthy volunteers

Promising interim phase I/II data on TNF-alpha kinoid in Crohn's disease

Phase I data support clinical activity of BMS-790052 in HCV genotype 1a/1b infection

EMA issues positive opinion for orphan status of AEZS-108 in ovarian cancer

Inovio Biomedical becomes Inovio Pharmaceuticals

Celldex begins phase II trial of CDX-1307 in bladder cancer

Geron reports preclinical data on heart failure therapeutic candidate GRNCM-1

FDA grants NeoPharm's IL13-PE38QQR orphan drug status for IPF

FDA grants orphan drug status to Allos' pralatrexate for bladder cancer

Primary endpoint met in phase I iCo-007 trial in diffuse diabetic macular edema

Gruenenthal claims novel bradykinin B1 receptor antagonists

Teva reports phase II data on talampanel in ALS

FDA approves Roxro Pharma's Sprix nasal spray for acute pain

AbD Serotec provides anti-idiotype antibodies as tools for research and development

LEAD Therapeutics presents novel antibacterial agents

Cerenis reports phase I data on CER-001 in cardiovascular disease

Amarillo Biosciences presents new phase II data on oral interferon for cold and flu

Chelsea Therapeutics reports on long-term safety trial of Northera

Pfizer and Washington University enter into collaboration agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...